OBJECTIVES: Expression of major histocompatibility complex (MHC) class II genes is almost exclusively regulated by the class II transactivator. A promoter polymorphism (-168A/G, rs3087456) in the MHC2TA gene was associated with increased susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction in a northern European population. However, no evidence of association of this MHC2TA variant with the two autoimmune diseases could be subsequently detected in independent cohorts. AIM: To test the aforementioned single nucleotide polymorphism and another G-->C change (nt1614 from coding sequence, rs4774) to analyse the haplotype pattern in this MHC2TA gene. METHODS: A case-control study was performed with 350 patients with rheumatoid arthritis, 396 patients with multiple sclerosis, 663 patients with inflammatory bowel disease (IBD) and 519 healthy controls from Madrid. Genotyping was ascertained by using TaqMan assays-on-demand on a 7900HT analyser, following the manufacturer's suggestions (Applied Biosystems, Foster City, California, USA). Haplotypes were inferred with the expectation-maximisation algorithm implemented by the Arlequin software. RESULTS: No independent association with these autoimmune diseases was found for either polymorphism in the Spanish cohorts tested. However, when haplotypes were compared between patients with rheumatoid arthritis and controls, a significant difference in their overall frequency distribution was observed, evidencing a protective haplotype (-168A/1614C, p = 0.006; odds ratio (OR) 0.7) and a risk haplotype (-168G/1614C, p = 0.019; OR 1.6). Patients with multiple sclerosis mirrored these results, but no effect on IBD was identified. CONCLUSIONS: The MHC2TA gene influences predisposition to rheumatoid arthritis and multiple sclerosis, but not to IBD. The -168G allele is not an aetiological variant in itself, but a genetic marker of susceptibility/protection haplotypes.
OBJECTIVES: Expression of major histocompatibility complex (MHC) class II genes is almost exclusively regulated by the class II transactivator. A promoter polymorphism (-168A/G, rs3087456) in the MHC2TA gene was associated with increased susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction in a northern European population. However, no evidence of association of this MHC2TA variant with the two autoimmune diseases could be subsequently detected in independent cohorts. AIM: To test the aforementioned single nucleotide polymorphism and another G-->C change (nt1614 from coding sequence, rs4774) to analyse the haplotype pattern in this MHC2TA gene. METHODS: A case-control study was performed with 350 patients with rheumatoid arthritis, 396 patients with multiple sclerosis, 663 patients with inflammatory bowel disease (IBD) and 519 healthy controls from Madrid. Genotyping was ascertained by using TaqMan assays-on-demand on a 7900HT analyser, following the manufacturer's suggestions (Applied Biosystems, Foster City, California, USA). Haplotypes were inferred with the expectation-maximisation algorithm implemented by the Arlequin software. RESULTS: No independent association with these autoimmune diseases was found for either polymorphism in the Spanish cohorts tested. However, when haplotypes were compared between patients with rheumatoid arthritis and controls, a significant difference in their overall frequency distribution was observed, evidencing a protective haplotype (-168A/1614C, p = 0.006; odds ratio (OR) 0.7) and a risk haplotype (-168G/1614C, p = 0.019; OR 1.6). Patients with multiple sclerosis mirrored these results, but no effect on IBD was identified. CONCLUSIONS: The MHC2TA gene influences predisposition to rheumatoid arthritis and multiple sclerosis, but not to IBD. The -168G allele is not an aetiological variant in itself, but a genetic marker of susceptibility/protection haplotypes.
Authors: J M Waldburger; K Masternak; A Muhlethaler-Mottet; J Villard; M Peretti; S Landmann; W Reith Journal: Immunol Rev Date: 2000-12 Impact factor: 12.988
Authors: Matthew R Lincoln; Alexandre Montpetit; M Zameel Cader; Janna Saarela; David A Dyment; Milvi Tiislar; Vincent Ferretti; Pentti J Tienari; A Dessa Sadovnick; Leena Peltonen; George C Ebers; Thomas J Hudson Journal: Nat Genet Date: 2005-09-25 Impact factor: 38.330
Authors: J Hampe; S H Shaw; R Saiz; N Leysens; A Lantermann; S Mascheretti; N J Lynch; A J MacPherson; S Bridger; S van Deventer; P Stokkers; P Morin; M M Mirza; A Forbes; J E Lennard-Jones; C G Mathew; M E Curran; S Schreiber Journal: Am J Hum Genet Date: 1999-12 Impact factor: 11.025
Authors: René Gödde; Klaus Rohde; Christian Becker; Mahammad R Toliat; Patricia Entz; Anita Suk; Norbert Müller; Eckhart Sindern; Michael Haupts; Sebastian Schimrigk; Peter Nürnberg; Jörg T Epplen Journal: J Mol Med (Berl) Date: 2005-03-16 Impact factor: 4.599
Authors: V Turcot; L Bouchard; G Faucher; A Tchernof; Y Deshaies; L Pérusse; P Marceau; F S Hould; S Lebel; Marie-Claude Vohl Journal: Hum Genet Date: 2011-06-24 Impact factor: 4.132
Authors: Paola G Bronson; Stacy Caillier; Patricia P Ramsay; Jacob L McCauley; Rebecca L Zuvich; Philip L De Jager; John D Rioux; Adrian J Ivinson; Alastair Compston; David A Hafler; Stephen J Sawcer; Margaret A Pericak-Vance; Jonathan L Haines; Stephen L Hauser; Jorge R Oksenberg; Lisa F Barcellos Journal: Hum Mol Genet Date: 2010-03-08 Impact factor: 6.150
Authors: J F Mendoza Rincón; A K Rodríguez Elias; J M Fragoso; G Vargas Alarcón; K Maldonado Murillo; M L Rivas Jiménez; R E Barbosa Cobos; S Jimenez Morales; G Lugo Zamudio; C Tovilla Zárate; J Ramírez Bello Journal: Rheumatol Int Date: 2015-09-08 Impact factor: 2.631
Authors: Ana Márquez; Jezabel Varadé; Gema Robledo; Alfonso Martínez; Juan Luis Mendoza; Carlos Taxonera; Miguel Fernández-Arquero; Manuel Díaz-Rubio; María Gómez-García; Miguel Angel López-Nevot; Emilio G de la Concha; Javier Martín; Elena Urcelay Journal: Eur J Hum Genet Date: 2009-04-01 Impact factor: 4.246